Pierrick Gj Fournier

List of Publications by Year
in descending order

37 papers	2,665 citations	361413 20 h-index	477307 29 g-index
37 all docs	37 docs citations	37 times ranked	3828 citing authors

#	Article	IF	Citations
1	Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Research, 2002, 62, 6538-44.	0.9	421
2	Molecular Biology of Bone Metastasis. Molecular Cancer Therapeutics, 2007, 6, 2609-2617.	4.1	405
3	Bisphosphonates and Cancer-Induced Bone Disease: Beyond Their Antiresorptive Activity: Figure 1.. Cancer Research, 2005, 65, 4971-4974.	0.9	217
4	TGF-Î²-RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases. Cancer Research, 2011, 71, 175-184.	0.9	203
5	Hypoxia and TGF-Î² Drive Breast Cancer Bone Metastases through Parallel Signaling Pathways in Tumor Cells and the Bone Microenvironment. PLoS ONE, 2009, 4, e6896.	2.5	189
6	Stable Overexpression of Smad7 in Human Melanoma Cells Impairs Bone Metastasis. Cancer Research, 2007, 67, 2317-2324.	0.9	187
7	The TGF-Î² Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell, 2015, 27, 809-821.	16.8	169
8	GLI2-Mediated Melanoma Invasion and Metastasis. Journal of the National Cancer Institute, 2010, 102, 1148-1159.	6.3	149
9	Angiostatin Inhibits Bone Metastasis Formation in Nude Mice through a Direct Anti-osteoclastic Activity. Journal of Biological Chemistry, 2003, 278, 45826-45832.	3.4	81
10	Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone, 2011, 48, 259-266.	2.9	81
11	In Vitro and In Vivo Antitumor Effects of Bisphosphonates. Current Medicinal Chemistry, 2003, 10, 173-180.	2.4	80
12	Halofuginone Inhibits the Establishment and Progression of Melanoma Bone Metastases. Cancer Research, 2012, 72, 6247-6256.	0.9	66
13	How Do Bisphosphonates Inhibit Bone Metastasis In Vivo. Neoplasia, 2010, 12, 571-578.	5.3	59
14	New insights into the role of T cells in the vicious cycle of bone metastases. Current Opinion in Rheumatology, 2006, 18, 396-404.	4.3	52
15	Lowering Bone Mineral Affinity of Bisphosphonates as a Therapeutic Strategy to Optimize Skeletal Tumor Growth Inhibition In vivo. Cancer Research, 2008, 68, 8945-8953.	0.9	42
16	FGF23 is elevated in multiple myeloma and increases heparanase expression by tumor cells. Oncotarget, 2015, 6, 19647-19660.	1.8	38
17	Halofuginone inhibits TGF-Î²/BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis. Oncotarget, 2017, 8, 86447-86462.	1.8	35
18	Brome mosaic virus-like particles as siRNA nanocarriers for biomedical purposes. Beilstein Journal of Nanotechnology, 2020, 11, 372-382.	2.8	34

#	Article	IF	Citations
19	Functionalized rare earth-doped nanoparticles for breast cancer nanodiagnostic using fluorescence and CT imaging. Journal of Nanobiotechnology, 2018, 16, 26.	9.1	32
20	Development of a functionalized UV-emitting nanocomposite for the treatment of cancer using indirect photodynamic therapy. Journal of Nanobiotechnology, 2018, 16, 19.	9.1	31
21	The vitamin D receptor is involved in the regulation of human breast cancer cell growth via a ligand-independent function in cytoplasm. Oncotarget, 2017, 8, 26687-26701.	1.8	22
22	Contribution of Macrophages and T Cells in Skeletal Metastasis. Cancers, 2020, 12, 1014.	3.7	19
23	TGFÎ²-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis. BoneKEy Reports, 2015, 4, 719.	2.7	17
24	Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice. Journal of Bone and Mineral Research, 2020, 37, 1446-1463.	2.8	11
25	TIE2 Induces Breast Cancer Cell Dormancy and Inhibits the Development of Osteolytic Bone Metastases. Cancers, 2020, 12, 868.	3.7	9
26	BMP7: A New Bone Metastases Prevention?. American Journal of Pathology, 2007, 171, 739-743.	3.8	5
27	Agents Targeting Prostate Cancer Bone Metastasis. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1079-1088.	1.7	5
28	In silico-designed mutations increase variable new-antigen receptor single-domain antibodies for VEGF165 neutralization. Oncotarget, 2018, 9, 28016-28029.	1.8	4
29	P48. Transforming growth factor Î² receptor I kinase inhibitor and bisphosphonates are additive to reduce breast cancer bone metastases. Cancer Treatment Reviews, 2008, 34, 37-38.	7.7	1
30	Tumor-Bone Cell Interactions in Bone Metastases. , 2010, , 9-40.		1
31	P16. Hypoxia and breast cancer bone metastasis: HIF-1Î± enhances TGF-Î² signaling and expression of prometastatic factors CXCR4 and VEGF. Cancer Treatment Reviews, 2008, 34, 18.	7.7	0
32	P32. Transforming growth factor-Î² (TGF-Î²) promotes prostate cancer bone metastases: Increased expression of pro-osteolytic genes and of PMEPA1, a new TGF-Î² signalling regulator. Cancer Treatment Reviews, 2008, 34, 25.	7.7	0
33	P57. Manipulating the bone mineral affinity of bisphosphonates to directly target cancer cells in the bone marrow. Cancer Treatment Reviews, 2008, 34, 42.	7.7	0
34	Correction: TGF-Î²-RI Kinase Inhibitor SD-208 Reduces the Development and Progression of Melanoma Bone Metastases. Cancer Research, 2011, 71, 2023-2023.	0.9	0
35	Tumorâ€“bone interactions: there is no place like bone. , 2015, , 13-28.		0
36	Transforming growth factor-Î² and its signaling pathway in skeletal complications of malignancy. , 2022, , 253-273.		0

#	Article	IF	Citations
37	TGF-Î²2 and BMP Signaling Pathways in Cancer and Bone: In Sickness and in Health. , 2020, , 281-293.		0